Immunotherapy has been a major breakthrough in the treatment of renal cell carcinoma (RCC). Researchers are investigating immunotherapy drugs in various combinations with other immunotherapy agents and vascular endothelial growth factor (VEGF) inhibitors and in various settings for the treatment of this disease.

Currently, the phase III KEYNOTE-564 trial is looking at pembrolizumab (Keytruda) as an adjuvant treatment for patients at high risk of recurrence following surgery, and is evaluating disease-free survival (DFS). The study is enrolling patients at the following sites in the UK, and can be found on our clinical trial database:

  • Edinburgh – Western General Hospital
  • Glasgow – Beatson West of Scotland Cancer Centre
  • Manchester – The Christie Hospital
  • London – Charing Cross Hospital
  • Middlesborough – James Cook University Hospital


In an interview with OncLive, KEYNOTE-564 lead investigator Dr Tian Zhang, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, Durham, USA, discussed this phase III study, as well as the progress that immunotherapy has made in the treatment of patients with RCC.

Read the interview in OncLive here